Skip to main content

Table 2 Demographic profile, laboratory parameters and drug dosages during maintenance therapy of ALL children studied with and without TPMT polymorphisms

From: Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia

Characteristic (median) Variant alleles (N = 5) Wild type (N = 35) p-Value
Maintenance follow-up (months) 14 (11.5-20.5) 14 (12–16) 0.782
Leucocytes (×109/L) 2.7 (2.35-4.23) 3.2 (2.56-4.14) 0.597
Platelet (×109/L) 265.4 (±105.8) 227.7 (±70.3) 0.286
Percentage of neutrophils 56.4 (±14.5) 55.5 (±12.9) 0.887
ANC (×109/L) 1.35 (1.08-2.68) 1.84 (1.30-2.20) 0.438
AST (mg/dL) 35.0 (33.7-47.5) 46.5 (30.5-54.0) 0.528
ALT (mg/dL) 28.5 (17.5-69.0) 61.0 (22.0-84.5) 0.159
Total Bilirubin (mg/dL) 0.43 (0.35-0.7) 0.59 (0.51-0.78) 0.141
Direct Bilirubin (mg/dL) 0.12 (0.11-0.22) 0.12 (0.09-0.15) 0.314